| Description | This product is a human monoclonal antibody that reacts with TNFRSF9. The antibody is expressed with mammalian cell transient expression system, serum-free and purified by affinity chromatography. The purity and integrity are tested via SDS-PAGE and SEC-HPLC analysis. Given an antigen, additional QC measures are also desired such as affinity testing and binding validation. Specifically, the antibody is provided in multiple formats for in vivo and in vitro assays. The Invivo version features greater than 95% purity, ultra-low endotoxin levels (<1 EU/mg or 0.1 EU/mg), and is preservative, stabilizer, and carrier protein-free. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | Human |
| Immunogen | Ectodomain of human 4-1BB recombinant protein. |
| Isotype | IgG |
| Expression Species | HEK293F or CHO |
| Conjugation | None |
| Purity | >95%, determined by SDS-PAGE and/or SEC-HPLC |
| Endotoxin | <1 EU/mg, determined by LAL method |
| Purification | Protein A affinity purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4⁰C within a week. For longer storage, aliquot and store at -20⁰C. |
| Application | WB; ELISA; FC; IP; FuncS; IF; Neut; ICC |
| Application Notes | The antibody is recommended for detection of TNFRSF9 by ELISA, FC, IP, FuncS, IF, Neut, ICC assays. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | TNFRSF9 |
| Alternative Name | TNFRSF9; tumor necrosis factor receptor superfamily, member 9; ILA; tumor necrosis factor receptor superfamily member 9; 4 1BB; CD137; CD137 antigen; T cell antigen ILA; T-cell antigen ILA; 4-1BB ligand receptor; homolog o |
| Gene ID | 3604 |
| UniProt | Q07011 |
| Research Area | Cell Biology; Immunology |
Figure 1 Anti-TNFRSF9 Monoclonal Antibody (V3S-0622-YC5675) in SDS-PAGE
SDS-PAGE analysis of V3S-0622-YC5675 in non-reduced and β-mercaptoethanol-reduced conditions. Gel stained for 30 minutes with Coomassie Blue. As a result of different β-mercaptoethanol-reduced proteins (Heavy chain and Light chain) migrate as about 50 kDa and 25 kDa, respectively. And non-reduced protein migrates as 180 kDa.
Figure 1 Anti-TNFRSF9 Monoclonal Antibody (V3S-0622-YC5675) in SDS-PAGE
Figure 2 Anti-TNFRSF9 Monoclonal Antibody (V3S-0622-YC5675) in SEC-HPLC
The purity of V3S-0622-YC5675 was greater than 94% as determined by SEC-HPLC.
Figure 2 Anti-TNFRSF9 Monoclonal Antibody (V3S-0622-YC5675) in SEC-HPLC
Figure 3 Anti-TNFRSF9 Monoclonal Antibody (V3S-0622-YC5675) in WB
Western blot analysis of V3S-0622-YC5675 was performed by loading Recombinant Human CD137 Protein (His Tag) (1 μg) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk.
Lane 1: Non-Reducing Antigen (1 μg)
Lane 2: Reducing Antigen (1 μg)
Figure 3 Anti-TNFRSF9 Monoclonal Antibody (V3S-0622-YC5675) in WB
Figure 4 Anti-TNFRSF9 Monoclonal Antibody (V3S-0622-YC5675) in ELISA
ELISA analysis of V3S-0622-YC5675 was performed by coating with Recombinant Human CD137 Protein (His Tag).
Figure 4 Anti-TNFRSF9 Monoclonal Antibody (V3S-0622-YC5675) in ELISA
